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in patients with active myocarditis  [8, 9] , several, albeit 
small, studies have suggested a potential effect of immu-
nosuppressive treatments in subgroups of patients with 
inflammatory cardiomyopathy  [10, 11] . In fact, it appears 
that patients with histological evidence for ongoing in-
flammation in the absence of residual viral genome in 
heart biopsy samples or evidence for heart-specific auto-
immunity might benefit from immunosuppression. An-
tiviral treatment, on the other hand, might be beneficial 
for patients suffering from acute viral myocarditis  [12] . 
Unfortunately, these studies were rather small and do not 
yet provide sufficient evidence to draw firm conclusions 
regarding generally accepted recommendations for the 
management of all patients with inflammatory heart dis-
ease. In order to translate recent progress in basic and 
preliminary clinical research into clinical practice, we 
therefore urgently need more data on these patients.
 The German Transregional Collaborative Research 
Centre ‘Inflammatory Cardiomyopathy – Molecular 
Pathogenesis and Therapy’  [13] , details of which are pub-
lished in  Cardiology , aims to establish a comprehensive 
research registry on the diagnostics, therapy and disease 
outcomes of patients with inflammatory cardiomyopa-
thy. Unfortunately, data collection and interpretation are 
greatly complicated by the low incidence of diagnosed 
acute myocarditis, the clinical variability, the lack of sen-
sitivity and specificity of routine cardiac tests and the 
 Inflammatory cardiomyopathy denotes a primary, ac-
quired cardiomyopathy, defined by the presence of a 
chronic inflammatory process  [1, 2] . Currently, inflam-
matory cardiomyopathy is estimated to account for 10–
50% of cases with dilated cardiomyopathy  [1–3] . Recent 
progresses in basic and clinical research support the con-
cept that acute, mostly virus-mediated myocarditis trig-
gers a complex system of interactions of host and infec-
tive agent-related factors, promoting heart failure devel-
opment. In this context, heart-specific autoimmunity 
might play a particularly important role  [3–5] .
 The term ‘inflammatory cardiomyopathy’ simply de-
notes the immunohistochemical detection of focal or dif-
fuse mononuclear infiltrates with  6 14 leukocytes/mm 2 
(CD3 + T lymphocytes and/or CD68 + macrophages) in
the myocardium, but largely neglects variations in the 
histological phenotype  [4, 6] . From this point of view, we 
still lack experience in linking morphological findings to 
a presumed specific clinical disease course. As an excep-
tion, we have to mention giant cell myocarditis, a distinct 
disease entity with typical histological appearance and 
unfavorable prognosis  [7] .
 The availability of novel molecular-biological tech-
niques has allowed the identification of genomes of vari-
ous infective agents supposed to trigger and promote in-
flammatory heart disease  [4] . Whereas historical studies 
failed to show an effect of immunosuppressive treatments 
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changing patterns of pathogenic cardiotropic microor-
ganisms  [3, 4, 14, 15] . From this point of view, it is practi-
cally impossible to cover all variables which might be-
come important for the understanding and management 
of inflammatory heart disease. In addition, the succes-
sive improvement of diagnostic modalities, i.e. cardiac 
MRI  [16] or molecular biology  [4, 14] , warrants ongoing 
and critical re-evaluation of data validity. As such, the 
currently available methodology will always be unsatis-
factory to answer our most recent questions. Thus, we are 
forced to – as the famous Danish physicist Niels Bohr 
(1885–1962) put it – get ‘dirty glasses clean with dirty 
towels and dirty dishwater’. Nevertheless, the described 
registry already covers a fairly large number of included 
cases and most of the variables currently considered as 
important in inflammatory cardiomyopathy. Despite im-
portant drawbacks, the registry might therefore repre-
sent a first step to the acquisition of relevant clinical, mi-
crobial and pathological data on inflammatory cardio-
myopathy patients, to the analyses of specific sub-groups 
as well as to potential therapeutic regimens. 
 I hope that the publication of this methodology paper 
prompts other centers in Europe to either join an existing 
registry or to build up their own collaborative databas-
es – ideally by using the same inclusion criteria and stan-
dardized protocols. This will be the only way to advance 
our knowledge on the disease course, diagnostic strate-
gies and appropriate treatments in such a complex dis-
ease entity as inflammatory cardiomyopathy. Getting 
dirty glasses clean with dirty towels, it works some-
how – but a philosopher would not believe it.
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